Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma

Piso, Pompiliu; Bektaş, H.; Werner, Ulrich; Schlitt, Hans J.; Kubicka, Stefan; Bornscheuer, A.; Manns, MP; Klempnauer, Jürgen

doi:10.1053/ejso.2000.1095

Cited by 69 publications

(27 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall morbidity in the present study was 35%, which compares well to data published by other groups [6,7,8,9]. It must be mentioned, however, that in these earlier studies, the HIPEC procedure and its indications were still being evaluated, resulting in increased morbidity and toxicity.…”

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Quality of Life in Peritoneal Carcinomatosis: A Prospective Study in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

et al. 2014

View full text Add to dashboard Cite

Background/Aims: Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion (HIPEC) can improve survival in selected patients with peritoneal carcinomatosis, but bear a significant risk of perioperative morbidity. The aim of this study was to prospectively evaluate the quality of life (QoL) following cytoreduction and HIPEC. Methods: In this study including 40 patients (65% females) with different primary tumors, the EORTC QLQ-C30 questionnaire was applied prior to CS and HIPEC as well as 3, 9, and 18 months postoperatively. Results: Global health status was not impaired significantly following HIPEC. Scales and symptom scores that deteriorated 3 months postoperatively (p < 0.05), that is, physical, role, and social functions as well as fatigue, pain, dyspnea, insomnia, and diarrhea, all returned to preoperative values within 9 months. Conclusions: Following cytoreductive surgery and HIPEC, QoL returns to preoperative levels within 9 months. Selected patients that are likely to benefit oncologically from HIPEC should not be denied this option for fear of reduced postoperative QoL. i 2014 S. Karger AG, Basel

show abstract

Section: Discussionsupporting

confidence: 85%

“…The procedure, however, bears a significant risk of morbidity and mortality [6,7,8,9]. In a study of 67 patients by Schmidt et al, the overall morbidity amounted to 34% [10] and the extent of surgery turned out to be the main contributing factor.…”

Section: Introductionmentioning

confidence: 99%

Quality of Life in Peritoneal Carcinomatosis: A Prospective Study in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Additionally, due to the features of advanced OC both at the time of its first manifestation and during relapse, PC is considered the ideal way of administering locoregional chemotherapy drugs, first at a normal temperature (118)(119)(120), and subsequently in hyperthermia (121)(122)(123)(124)(125)(126). The intraperitoneal administration of chemotherapy drugs allows for the optimal concentration and distribution of these substances, with lower systemic toxic effects compared to an intravenous method.…”

Section: Topic 7: Is It Right From An Ethical Point Of View To Subjecmentioning

confidence: 99%

1^stEvidence-based Italian Consensus Conference on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Ovarian Cancer

Cavaliere

Cirocchi

Catena

et al. 2017

Tumori

View full text Add to dashboard Cite

Ovarian cancer (OC) remains relatively rare, although it is among the top 4 causes of cancer death for women younger than 50. The aggressive nature of the disease and its often late diagnosis with peritoneal involvement have an impact on prognosis. The current scientific literature presents ambiguous or uncertain indications for management of peritoneal carcinosis (PC) from OC, both owing to the lack of sufficient scientific data and their heterogeneity or lack of consistency. Therefore, the Italian Society of Surgical Oncology (SICO), the Italian Society of Obstetrics and Gynaecology, the Italian Association of Hospital Obstetricians and Gynaecologists, and the Italian Association of Medical Oncology conducted a multidisciplinary consensus conference (CC) on management of advanced OC presenting with PC during the SICO annual meeting in Naples, Italy, on September 10-11, 2015. An expert committee developed questions on diagnosis and staging work-up, indications, and procedural aspects for peritonectomy, systemic chemotherapy, and hyperthermic intraperitoneal chemotherapy for PC from OC. These questions were provided to 6 invited speakers who answered with an evidence-based report. Each report was submitted to a jury panel, representative of Italian experts in the fields of surgical oncology, gynecology, and medical oncology. The jury panel revised the reports before and after the open discussion during the CC. This article is the final document containing the clinical evidence reports and statements, revised and approved by all the authors before submission.

show abstract

“…Recently, a more aggressive treatment strategy called cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) has been developed with curative intent (Yonemura et al, 2005). CRS and HIPEC are also widely accepted as standard of care to achieve long-term survival in patients with PM from colorectal carcinoma, appendiceal cancer and diffuse malignant peritoneal mesothelioma (Verwaal, 2009;Piso et al, 2001;Yan, Welch, Black, & Sugarbaker, 2009). …”

Section: Introductionmentioning

confidence: 99%

Effects of Laparosopic Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis from Gastric Cancer

Yonemura¹,

Canbay²,

Sako³

et al. 2014

CCO

View full text Add to dashboard Cite

Background: The purpose of this manuscript is to report the direct effects of hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer-patients with peritoneal metastasis (PM). Materials and Methods:Thirty-five patients with PM were enrolled, and were treated with neoadjuvant laparoscopic HIPEC (LHIPEC). LHIPEC was performed at 42 to 43 centigrade for 60 minutes adding 3 liter of saline plus 12.5mg/m2 of Mitomycin C with Cisplatin (50mg/m 2 ). Second session of LHIPEC was done one month after the first LHIPEC in all cases. At the second session of LHIPEC, ascites volume, peritoneal cytology and peritoneal cancer index (PCI) were examined again.Results: Intraoperative complications of bowel injury were experienced in one and three at 1 st and 2 nd session of laparoscopy, respectively. There was no mortality after LHIPEC. Ascites was completely disappeared in 17 of 34 patients at the second session of laparoscopy. PFCCs had been detected in 28 (80.0%) patients at the 1 st session, and the positive cytology changed to be negative in 16 (57.1%) of 28 patients at the second session. PCI at the 2 nd session (12.5 ± 10.5) was significantly lower than that at the 1 st session (16.8 ± 9.6) (P=0.023). PCI levels at the 2 nd session changed to be 0 in 6 patients. Conclusion:This new method is not only a safe and convenient method for predicting feasibility of complete cytoredution, but also an effective treatment to control malignant ascites and to eradicate PFCCs before cytoreductive surgery. Furthermore, LHIPEC can reduce PCI levels.

show abstract

Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma

Cited by 69 publications

References 12 publications

Quality of Life in Peritoneal Carcinomatosis: A Prospective Study in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Quality of Life in Peritoneal Carcinomatosis: A Prospective Study in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

1^stEvidence-based Italian Consensus Conference on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Ovarian Cancer

Effects of Laparosopic Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis from Gastric Cancer

Contact Info

Product

Resources

About

Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma

Cited by 69 publications

References 12 publications

Quality of Life in Peritoneal Carcinomatosis: A Prospective Study in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Quality of Life in Peritoneal Carcinomatosis: A Prospective Study in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

1stEvidence-based Italian Consensus Conference on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Ovarian Cancer

Effects of Laparosopic Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis from Gastric Cancer

Contact Info

Product

Resources

About

1^stEvidence-based Italian Consensus Conference on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Ovarian Cancer